Rangeley Capital’s Sage Therapeutics SAGE Stock Holding History

Rangeley Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-730,000	Closed	-$6.66M	–	138
2025 Q2	$6.66M	Buy	730,000 +345,313	+90%	+$2.54M	7.94%	1
2025 Q1	$3.06M	Buy	+384,687	New	+$2.82M	3.28%	13

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rangeley Capital's SAGE Position: Q3 2025 in Review

Rangeley Capital sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 730,000 shares — an estimated $6.66M sold.

Rangeley Capital first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $6.66M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Rangeley Capital reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Rangeley Capital sold 730,000 Sage Therapeutics shares in Q3 2025, an estimated $6.66M.
Rangeley Capital first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
Rangeley Capital's Sage Therapeutics position peaked at $6.66M in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Rangeley Capital's 13F filing for Q3 2025, filed 14 Nov 2025.